Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"An interesting analysis to consider is the total short covering over the most recently reported period compared to total volume for the same period. After all, our volume has been very low as of late. WHEN WE ARE SEEING HIGH SHORT COVERING WITH LOW VOLUME TRADING, THIS WILL BE A GOOD SIGN."
well casperzelkuswhatever i must admit that a cover in this scenario you present where retail shorty is doing all the buying into selling motivated by an ever accelerating higher pps would indeed be a good sign. my only question to you is, when you finally cover will you be rushing to the cover exit as well with the herd or will you display a modicum of trading intelligence and exit before the slaughter of retail shorty, "THE TRUE BAGHOLDERS"?
LOL!!!!!!!!!!!!!!!!!!
Boo:with the short position flat to down .9%/277,800 shares at 55 DAYS to COVER as of 2/13/2015, it is of little wonder the schizophrenia this mb`s bashers display regularly is as vitriolic and puerile as it is. i imagine the basher/retail shorty diet of tums, pepcid, and quaaludes these days leaves them feeling much more like their short NAVB sentiment/play is of purgatory or dante`s inferno rather than the much sought after short Shangri La of 2011. c`est la vie.....
hey marty: is pleading your case on a mb using the "who ya gonna believe... me or your lyin` eyes" tactic part of an overall counsel sanctioned defense stratagem of projection and deception? if not then why the exhibition on your part in which aspects of may be used against ya in a court of law? upside? regardless, the antics and optics are appreciated....
BooDog: thank-you for sharing...i look forward to your TA as/when presented.
hey casperzelkuswhatever: i guess the shorts didn`t get the memo to knock down the pps today with the volume being what it is and after all it`s going to...50cents...25cents....ZERO?? one would think shorts and their bashers would be on the same page, go figure. maybe tomorrow will be a better day for the chicken little dance casperzelkuswhatever.
"They have been doing this for 3 years, welcome to the real world. Many many pissed off investors in this longer than you."
and yet u are still posting here on this mb peter, a supposed NAVB long, constantly b & minng about NAVB after supposedly exiting your NAVB position. peter, a better alias for you would be schitzo joe. regardless, investing much less SPECULATIVE micro biotech investing is way over over your head. suggest passbook savings accounts though i imagine you`ll continue b & ming because...that`s what you do.
PATHETIC and actually a bit laughable.
BooDog: same here as to Monday PR. bought some more yesterday @ a $1.61. will buy more next month too and shorty is paying for all of my buys since 2011. thanks casper & diddo! have a great weekend BooDog, i shall!
Navidea to Report Preliminary 2014 Revenue and Present at BIO CEO & Investor Conference February 9
Published: Feb 2, 2015 3:17 p.m. ET
DUBLIN, Ohio, Feb 02, 2015 (BUSINESS WIRE) -- Navidea Biopharmaceuticals, Inc. (nyse mkt:NAVB), today announced that the Company will report preliminary fourth quarter and full year 2014 revenues and provide a business update before market open on Monday, February 9, 2015. In addition, Rick Gonzalez, Chief Executive Officer, will present at the 17th Annual BIO CEO and Investor Conference at 10:00 am EST on February 9, 2015.
A live webcast of Mr. Gonzalez’s BIO CEO presentation can be accessed at the following URL: http://www.veracast.com/webcasts/bio/ceoinvestor2015/98108167461.cfm. An archived version of the webcast will be available two hours following the presentation and can be accessed within the Investors' section of the Navidea website at www.navidea.com.
http://www.marketwatch.com/story/navidea-to-report-preliminary-2014-revenue-and-present-at-bio-ceo-investor-conference-february-9-2015-02-02?siteid=nbsh
BooDog: thank-you though my preference here on this mb is to take in the TA that you(a few others too) at least still provide. there was more at one time but i'm of the belief with the garbage bashing that frequents this mb more and more informative TA has dropped off. most always it seems the antics and stupidity of a few can/does ruin the synergy.
NEWS>>>>>1."Lymphoseek® Performance vs. Sulfur Colloid in Breast Cancer Patients Published in Annals of Surgical Oncology; Fewer Nodal Dissections Required" http://www.marketwatch.com/story/lymphoseek-performance-vs-sulfur-colloid-in-breast-cancer-patients-published-in-annals-of-surgical-oncology-fewer-nodal-dissections-required-2015-01-29?siteid=nbsh
2.CD206 patent application
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=/netahtml/PTO/search-adv.html&r=1&p=1&f=G&l=50&d=PG01&S1=navidea&OS=navidea&RS=navidea
COMPOSITIONS, METHODS AND KITS FOR DIAGNOSING AND TREATING CD206 EXPRESSING CELL-RELATED DISORDERS
Abstract
A method of diagnosing a CD206 expressing cell-related disorder by administering a pharmaceutical composition to a subject, the composition including a carrier molecule having a detectable moiety attached thereto. The carrier molecule has a dextran backbone, and at least one receptor substrate conjugated, directly or indirectly, to the dextran backbone, wherein the receptor substrate is chosen so as to specifically bind to CD206. A method of treating a CD206 expressing cell-related disorder is also provided, as well as an ex vivo method and kit for quantitating the number of cells expressing CD206 in a bodily fluid.
note: whiners need not read....
casper/zelkus: of course NAVB longs have been disappointed at times but to threaten violence towards company officers is the purview of immature school children who in person experience has shown to be the first ones to run behind teacher`s skirt in the advent of a face to face. instead of behaving as a schizoprhrenic wack job on this mb due to an inability to accept biotec volatility, would it not be "adult normal" to sell your NAVB position so as to avoid embarrassing yourself again, again, and again? you are in way over your head and because i do not rant, scream, threaten violence, etc... due to NAVB`s pps volatility simply means i prefer not to contribute to this mb in a manner that suits your demented approval. rather and by simply conducting ongoing DD at my average pps to acquire NAVB, coupled with my ongoing return(trading & lending), NAVB`s THERAPEUTIC potential, inmo means the decreasing risk is more than worth the play. if i`m wrong then i move on though due to my average cost. as of yesterday`s close i`m just below a double. NAVB is a biotech that will lose big, win big or pay off somewhere in between. obviously as you have proven often on this mb via posted temper tantrums children that play the market just can`t deal with two of the three said biotec outcomes. have ya thought about tiddlywinks?....pathetic.
LOL casper... takin' a cinderblock to B.L.'s head, anybody's head for that matter when ya couldn't even lift said cinder block much less hit the floor with the drop of a hat. bravado and the threat of violence from one's computer is truly ridiculous and pathetic zelkus. you and diddo are very capable in providing laughs aplenty on this mb, thanks!
per diddobuyer:"I lost faith in this company's ability to execute and took my losses yesterday at 1.06.". as this most recent bear raid took out the weak and/or whining NAVB holds not only did i buy 2.95k/1.2% @$1.01 & $1.03 i bought below peter`s sell and it now has closed in the green.
go figure....lol!
peter, your full poopy diaper disgruntled long routine with the occasional anti-semitic comment is rather worn even for someone as inept/pathetic as you constantly present on this mb. a new bashing routine from ya would at least suggest you have a modecom of imagination, yes? NAVB under the helm of RG will successfully manage and grow the revenue from LYMPHOSEEK along with the ever expanding manocept platform, now, going forward. biotech successful investing is by no means a guarantee as you obviously/foolishly believe. i sure hope that when you sell your imaginary NAVB shares ya give the longs a heads up as that possibly buying your imaginary shares on the cheap may more than compensate the witnessing of one that will in all likelyhood remain a pathologic individual. keep the blah, blah, and the names coming...it`s what you do. lol....
misery loves company
Boodog: fyi/ next short report is 10/24/2014
http://www.nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch
Tulip? if indeed the person on the left is Tom Tulip the caption is not applicable unless and of course we all are two dimensional, emotionally driven, chemically dependent retail traders/longs.
FDA Approves Expanded Use of Navidea’s Lymphoseek® for Lymphatic Mapping in Solid Tumors
http://ir.navidea.com/phoenix.zhtml?c=68527&p=irol-newsArticle&ID=1977807
FDA Approves Expanded Use of Navidea’s Lymphoseek® for Lymphatic Mapping in Solid Tumors
- Lymphoseek® (technetium Tc 99m tilmanocept) Injection Use for Sentinel Lymph Node detection also expanded to include Breast Cancer and Melanoma -
- Expanded Lymphoseek indication increases the addressable market with the potential to benefit up to 1.2 million solid tumor patients in U.S. annually -
- Company to Host Conference Call on Wednesday, October 15, 2014, 8:30 a.m. EDT -
DUBLIN, Ohio--(BUSINESS WIRE)--Oct. 15, 2014-- Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has approved the Supplemental New Drug Application (sNDA) for the expanded use of Lymphoseek® (technetium Tc 99m tilmanocept) injection for lymphatic mapping in solid tumors and adding Sentinel Lymph Node detection for breast cancer and melanoma to the approved indications. Lymphoseek is now indicated for:
Lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in patients with solid tumors for which this procedure is a component of intraoperative management
Guiding Sentinel Lymph Node Biopsy (SLNB) using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma (SCC) of the oral cavity, breast cancer or melanoma.
The FDA also allowed expanded utilization of Lymphoseek with or without scintigraphic imaging, known as lymphoscintigraphy, to enable pre-operative imaging and mapping of lymph nodes to facilitate node localization during surgical procedures. Lymphoseek is the first and only FDA-approved radiopharmaceutical agent for sentinel lymph node detection, is the only FDA-approved agent for lymphatic mapping of solid tumors, and will be immediately available using existing reimbursement codes for this expanded population of cancer patients.
“Lymphoseek is the now the only agent approved by the FDA for lymphatic mapping across solid tumors when used as a component of surgical management. This significantly expands the potential market for Lymphoseek and materially enhances the Company’s ability to promote the use of Lymphoseek in solid tumor cancers where assessment of lymphatic involvement is critical to properly staging the disease, especially colorectal, gynecological, lung and prostate cancers,” said Michael Goldberg, M.D., Interim Chief Executive Officer. “We are highly encouraged by the expanded FDA approval and believe that Lymphoseek now has the potential to become a standard-of-care in lymphatic mapping and sentinel lymph node biopsy for the staging and prognosis of upwards of 1.2 million patients diagnosed with solid tumors annually in the U.S. We are eager to discuss the new label with surgeons and oncologists whose patients should benefit from the improved data resulting from better utilization of lymphatic mapping and Sentinel Lymph Node Biopsy procedures.”
“Based on our clinical experience in melanoma and head and neck cancers, Lymphoseek appears to be an effective agent for cancer staging to guide pre- and intra-operative patient management and post-surgical treatment thereby avoiding unnecessary surgical interventions, reducing surgical time and limiting potential complications with associated morbidity,” commented Dr. Stephen Y. Lai, M.D., Ph.D., FACS, Associate Professor, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center. “The ability of Lymphoseek to accurately identify sentinel lymph nodes in patients, demonstrated in clinical evidence from more than 500 patients, may not only improve diagnostic accuracy, but also enable more efficient and appropriate patient care and provide us with greater precision during surgery to detect lymph nodes with the highest likelihood of harboring tumor metastases.”
“The success of lymphatic mapping and sentinel lymph node biopsy is dependent upon a radiopharmaceutical’s ability to concentrate in the lymph nodes most likely to contain cancer,” said H. William Strauss, M.D., Attending Physician Emeritus, Molecular Imaging and Therapy Service at Memorial Sloan-Kettering Cancer Center. “Lymphoseek, with its specifically-designed ability to target molecular markers in tumor-draining lymph nodes, has shown through clinical studies in breast cancer, melanoma and certain head and neck cancers, to possess a high degree of sensitivity and accuracy. Based on the reliable performance of Lymphoseek as demonstrated in these tumor-types, this approval opens up potential diagnostic imaging opportunities broadly across all forms of solid tumors.”
The expanded approval is supported by data from Navidea’s combined analysis of Lymphoseek’s pivotal prospective Phase 3 data in melanoma, breast cancer, and certain head and neck cancers from more than 500 subjects. An integrated analysis of data from all three studies showed positive diagnostic performance of Lymphoseek across the solid tumor types studied. The findings indicate that Lymphoseek accurately identified lymph nodes for assessment in the trial subjects, and is likely to be predictive of overall node pathology status. To date, no clinically significant drug-related adverse reactions have been reported. Lymphoseek has no contraindications and the most common adverse reactions were injection site irritation and/or pain (<1%).
In the approval action letter, the FDA also outlined a post-marketing requirement for initiation of a pediatric study in solid tumor cancer with a target date for submission in 2018.
Conference Call Details
Navidea will host a conference call with the investment community to discuss the sNDA scheduled for Wednesday, October 15, 2014 at 8:30 a.m. EDT. Investors and the public are invited to access the live webcast through the link below. Participants who would like to ask questions during the question and answer session following the presentation must participate by telephone also. Participants are encouraged to log-in and/or dial-in fifteen minutes before the conference call begins. The webcast replay is expected to be available on our investor website, http://ir.navidea.com, approximately two to four hours after the live event.
Event: Navidea Biopharmaceuticals sNDA Approval Call
Date/Time: Wednesday, October 15, 2014 at 8:30 a.m. EDT
Webcast Link:
http://public.viavid.com/index.php?id=111146
Dial-in Number – US: 1-877-407-0789
Dial in Number – Int’l: 1-201-689-8562
Replay
A webcast replay will be available on the Investor Relations section of our website at http://ir.navidea.com.
nothin`n for ya here diddo & casper...ya`ll can go back to poundin` sand, lol!
DUBLIN, Ohio, Sep 26, 2014 (BUSINESS WIRE) -- Navidea Biopharmaceuticals, Inc. (nyse mkt:NAVB) has announced that that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing authorization for Lymphoseek® 250 micrograms kit for radiopharmaceutical preparation (tilmanocept) in the European Union (EU). The recommendation is for Lymphoseek use in imaging and intraoperative detection of sentinel lymph nodes draining a primary tumor in adult patients with breast cancer, melanoma, or head and neck oral cavity squamous cell carcinoma.
The CHMP's positive recommendation will be reviewed by the European Commission, which has the authority to approve medicinal products for use in the 28 countries of the European Union and generally follows the recommendations of the CHMP. Navidea expects the European Commission to issue its final decision on the marketing authorization for Lymphoseek later this year.
"This positive CHMP opinion moves Lymphoseek closer to becoming the first and only sentinel lymph node detection agent approved in all 28 member countries of European Union,” said Michael Goldberg, M.D., Interim CEO of Navidea. "We believe Lymphoseek is differentiated in its ability to reliably and accurately locate sentinel lymph nodes draining a tumor, to help more effectively stage cancer and inform post-surgical treatment, and to decrease patient morbidity. We are increasingly excited by the global opportunity for Lymphoseek as we build upon our approval in the U.S. and prepare to make the product available next year to physicians in Europe looking to provide the best care for their patients.”
“Current medical practices for head and neck cancers call for removal of large numbers of lymph nodes, lymph node dissection, even in patients without proven lymph node metastasis,” said Professor Remco de Bree, M.D., Ph.D., Department of Otolaryngology-Head and Neck Surgery, VU University Medical Center, Amsterdam, The Netherlands. “Using the common practice of elective treatment of the neck, large numbers of patients undergo unnecessary extensive surgical procedures, which are associated with the risk of decreased shoulder function, decreased quality of life and increased costs. The practice of Sentinel Lymph Node Biopsy (SLNB) may offer a less invasive and equally predictive alternative for patient staging and directing adequate treatment of the neck. We welcome the addition of Lymphoseek in Europe as an approved sentinel lymph node detection agent with the potential to offer surgeons the ability to reliably and accurately guide SLNB procedures.”
The opinion of the CHMP was based on positive and consistent results from Lymphoseek’s three pivotal prospective Phase 3 studies in melanoma, breast cancer, and certain head and neck cancers and included associated analysis of the combined data from more than 500 subjects. All three studies showed positive diagnostic performance of Lymphoseek across the solid tumor types studied. To date, no clinically significant drug-related adverse reactions have been reported. Lymphoseek has no contraindications and the most common adverse reactions were injection site irritation and/or pain (<1%).
Lymphoseek is approved in the U.S. by the U.S. Food and Drug Administration (FDA) for use in lymphatic mapping to assist in the detection of tumor-draining lymph nodes in patients with breast cancer or melanoma and for use in guiding sentinel lymph node biopsy in certain oral cancer patients. Lymphoseek is also the subject of a supplemental New Drug Application (sNDA) currently under review by the FDA, related to broader and more flexible utilization in lymphatic mapping procedures.
http://www.marketwatch.com/story/navideas-lymphoseek-recommended-by-chmp-for-european-approval-in-sentinel-lymph-node-detection-for-melanoma-breast-and-certain-head-and-neck-cancers-2014-09-26?siteid=nbsh
New Drug Registration/Approval Process in China(DDbuyer/IV/otl)(
http://www.healthinlink.com/down/An%20Overview_New%20Drug%20Registration%20System%20and%20Approval%20Process%20in%20China.pdf
http://lifetechcapital.com/ltc/wp-content/uploads/2014/09/Morning-Note-09-04-14-NAVB.pdf
kei: PM(Platinum Montaur) is the largest shareholder for 6-7 years now. simply a filing that details their said, present, ongoing hold(common, preferred,calls, puts). as to new share holders there is an ever increasing number as well, as shown:
12 New Institutional Holders
238,096 New Total Shares Held
Click on the column header links to resort ascending (?) or descending (?).
Owner Name Date Shared Held Change (Shares) Change (%) Value (in 1,000s)
STRATOS WEALTH PARTNERS, LTD. 06/30/2014 45,535 45,535 New 58
PRINCIPAL FINANCIAL GROUP INC 06/30/2014 34,934 34,934 New 44
MILLENNIUM MANAGEMENT LLC 06/30/2014 34,100 34,100 New 43
JANE STREET GROUP, LLC 06/30/2014 28,119 28,119 New 36
TOWER RESEARCH CAPITAL LLC 06/30/2014 18,483 18,483 New 23
GSA CAPITAL PARTNERS LLP 06/30/2014 17,800 17,800 New 23
RIDGEWORTH CAPITAL MANAGEMENT LLC 06/30/2014 12,861 12,861 New 16
NUVEEN ASSET MANAGEMENT, LLC 06/30/2014 12,159 12,159 New 15
D. E. SHAW & CO., INC. 06/30/2014 11,045 11,045 New 14
CABOT MONEY MANAGEMENT INC 06/30/2014 10,000 10,000 New 13
FINANCIAL ADVISORY GROUP 06/30/2014 10,000 10,000 New 13
BANK OF MONTREAL /CAN/ 06/30/2014 3,060 3,060 New 4
Read more: http://www.nasdaq.com/symbol/navb/institutional-holdings/new#ixzz3BDvWCWr5
not a dumb question at all kei. please regard the quoted line below. Platinum Montaur is the focus of this filing.
Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
"INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES"
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
Form 3 filing 8/12/2014(NAVIDEA BIOPHARMACEUTICALS, INC. [ NAVB ])
http://www.sec.gov/Archives/edgar/data/810509/000114036114033982/xslF345X02/doc1.xml
those that whine, whine, whine and constantly complain peevishly about past trading decisions possibly induced by inaccurate revenue forecasts via the "professionals" in conjunction with poorly conducted DD, it would seem are ever relegated to continued "p & m" ever while conducting certain bodily functions all the while from a sitting position. better to realise that said previous trading decision(s) is water under the bridge also poorly timed then either moving on or averaging down. option one it seems to me is a pathology that can only lead to more whining, hardly a satisfactory way to live in a world where there are so many avenues to success. get over yourself peter, you`ll like yourself better.
"The over estimated the market even with the 6 month CRL delay so stop touting their estimates as a reason to buy this stock, it is not a reason to buy unless you an ignoramus."
based on your logic and sloppy liguistics peter would you not then be past an "ignoramus" for holding over three+ years? purely from a consistency perspective of course.
peter, your "financial adviser" is inept and his client is asleep at the wheel, or a fool(?). c`est la vie.....
Uri is to busy pursuing then counting PPVA's profits gained via the selling, arbitrage, and plain ole trading of NAVB. who can blame him, I don't.
Wrinkles: copy/paste from yahoo board per your request and well done indeed it was/is.
techread • 7 hours ago Flag
wow...
Took a few minutes to read the latest over on IV. Really, a few astute posters call out DD on his latest round of "it's not what you think"...and once again the subject gets re-directed. I read every filing. Pay attention to what they don't say as much as what they do. Really, PM gave them to MG? Those are reportable plain and simple. PM can go over the blocker, as they did in 2012 and fully report. The blocker is designed to protect the common shareholder. The holes in the PM blocker are exactly why additional blockers were added to the Crede deal.. "If" PM didn't once again unload, the only other reason to convert and tuck them under the radar is a proxy. Take a look at the ongoing and very ugly proxy battle being waged by PM on ECTE. Really? MG is the PM designated BOD member yet he's no longer associated with them? Let's just call a spade a spade. DD is PM's mouthpiece plain and simple. Next up in the que for NAVB is a balance sheet restructure and that will likely give PM a huge new block of shares to wash-rinse. They latest conversions are the last stage of the rinse cycle. Next comes the repeat at the low SP. NAVB holders are stuck with this chronic dilution until the company is cash-flow positive and no longer needs them. MG bullied his way onto our BOD and don't think for a minute he doesn't represent PM first, everyone else last. If you're into TA plot the PM conversion dates on a momentum chart and you'll know exactly when to expect the next wave of sell pressure. All IMHO of course.
BOL all.
techread • 5 hours ago Flag
There are only 3 reasons to give up a senior Preferred Share for a common:
1. You're forced to by an auto-conversion feature (N/A in this case).
2. You sell and/or arbitrage them. A common tactic by arbitrage hedge funds.
3. You are mounting a proxy or proxy threat and need the voting power
techread • 5 hours ago Flag
inside....they are required to report as one. same as their other holdings. Read the most recent ECTE filings as an example....Uri, Mark, etc. are all required to report collectively and beneficially. They "report" at the 9.99% level as that represents their potential max voting power w/o giving 60 days notice that they are waiving the blocker. In essence the shares cannot and never have been separated. Also refer to 2012 when they reported owning only 3M shares, yet exceeded the blocker due to having derivative positions. We have not seen 2 separate entities report yet because they don't exist as separate from a reporting standpoint. Owners over 5% have requirements as well. Directors have to report everything over 0%. That's my opinion and with that said respect yours as well. GLTY
techread • 4 hours ago Flag
We're looking at the same thing through different lenses (which is actually good). My point is that it doesn't matter. Both PM and PPVA along with all their other entities are controlled by the same person, and as such are required to be reported collectively. In other words, if PM + PPVA collectively own more than 10% as we speak, they were required to have already reported that to us. If shares went to MG as DDb suggested, that would also have been required to have been reported to us....and I don't mean in July. If they do currently own more than 10%, and have not reported it, I would question their proxy motives as well as ability to vote the unreported shares. Based on everything reported through last week, IMO an arbitrage sale and/or long sale (disposition) is most likely given the facts. PM doesn't want you to think they are selling, and as in the past will go out of their way to run us in another direction.